SIGA Quote, Financials, Valuation and Earnings

Chimerix has a net margin of 13.43% compared to SIGA Technologies's net margin of -87996.15%. SIGA Technologies's return on equity of 52.07% beat Chimerix's return on equity of -48.22%.

SIGA Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand Chimerix has an analysts' consensus of -- which suggests that it could grow by 151.5%. Given that Chimerix has higher upside potential than SIGA Technologies, analysts believe Chimerix is more attractive than SIGA Technologies.

SIGA Technologies has a beta of 0.891, which suggesting that the stock is 10.87% less volatile than S&P 500. In comparison Chimerix has a beta of 1.018, suggesting its more volatile than the S&P 500 by 1.827%.

SIGA Technologies has a quarterly dividend of $0.60 per share corresponding to a yield of 0%. Chimerix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SIGA Technologies pays 47.21% of its earnings as a dividend. Chimerix pays out -- of its earnings as a dividend. SIGA Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

SIGA Technologies quarterly revenues are $10M, which are larger than Chimerix quarterly revenues of $26K. SIGA Technologies's net income of $1.3M is higher than Chimerix's net income of -$22.9M. Notably, SIGA Technologies's price-to-earnings ratio is 5.00x while Chimerix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SIGA Technologies is 2.48x versus -- for Chimerix. Usually stocks with elevated PS ratios are considered overvalued.

Emergent BioSolutions has a net margin of 13.43% compared to SIGA Technologies's net margin of 40.45%. SIGA Technologies's return on equity of 52.07% beat Emergent BioSolutions's return on equity of -35.94%.

SIGA Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand Emergent BioSolutions has an analysts' consensus of $12.00 which suggests that it could grow by 44.58%. Given that Emergent BioSolutions has higher upside potential than SIGA Technologies, analysts believe Emergent BioSolutions is more attractive than SIGA Technologies.

SIGA Technologies has a beta of 0.891, which suggesting that the stock is 10.87% less volatile than S&P 500. In comparison Emergent BioSolutions has a beta of 1.594, suggesting its more volatile than the S&P 500 by 59.352%.

SIGA Technologies has a quarterly dividend of $0.60 per share corresponding to a yield of 0%. Emergent BioSolutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SIGA Technologies pays 47.21% of its earnings as a dividend. Emergent BioSolutions pays out -- of its earnings as a dividend. SIGA Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

SIGA Technologies quarterly revenues are $10M, which are smaller than Emergent BioSolutions quarterly revenues of $283.8M. SIGA Technologies's net income of $1.3M is lower than Emergent BioSolutions's net income of $114.8M. Notably, SIGA Technologies's price-to-earnings ratio is 5.00x while Emergent BioSolutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SIGA Technologies is 2.48x versus 0.40x for Emergent BioSolutions. Usually stocks with elevated PS ratios are considered overvalued.

Geovax Labs has a net margin of 13.43% compared to SIGA Technologies's net margin of -208.48%. SIGA Technologies's return on equity of 52.07% beat Geovax Labs's return on equity of -575.49%.

SIGA Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand Geovax Labs has an analysts' consensus of $14.60 which suggests that it could grow by 546.02%. Given that Geovax Labs has higher upside potential than SIGA Technologies, analysts believe Geovax Labs is more attractive than SIGA Technologies.

SIGA Technologies has a beta of 0.891, which suggesting that the stock is 10.87% less volatile than S&P 500. In comparison Geovax Labs has a beta of 3.242, suggesting its more volatile than the S&P 500 by 224.241%.

SIGA Technologies has a quarterly dividend of $0.60 per share corresponding to a yield of 0%. Geovax Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SIGA Technologies pays 47.21% of its earnings as a dividend. Geovax Labs pays out -- of its earnings as a dividend. SIGA Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

SIGA Technologies quarterly revenues are $10M, which are larger than Geovax Labs quarterly revenues of $2.8M. SIGA Technologies's net income of $1.3M is higher than Geovax Labs's net income of -$5.8M. Notably, SIGA Technologies's price-to-earnings ratio is 5.00x while Geovax Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SIGA Technologies is 2.48x versus -- for Geovax Labs. Usually stocks with elevated PS ratios are considered overvalued.

Tonix Pharmaceuticals Holding has a net margin of 13.43% compared to SIGA Technologies's net margin of -503.65%. SIGA Technologies's return on equity of 52.07% beat Tonix Pharmaceuticals Holding's return on equity of -150.01%.

SIGA Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand Tonix Pharmaceuticals Holding has an analysts' consensus of $5.83 which suggests that it could grow by 1413.97%. Given that Tonix Pharmaceuticals Holding has higher upside potential than SIGA Technologies, analysts believe Tonix Pharmaceuticals Holding is more attractive than SIGA Technologies.

SIGA Technologies has a beta of 0.891, which suggesting that the stock is 10.87% less volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding has a beta of 2.232, suggesting its more volatile than the S&P 500 by 123.214%.

SIGA Technologies has a quarterly dividend of $0.60 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SIGA Technologies pays 47.21% of its earnings as a dividend. Tonix Pharmaceuticals Holding pays out -- of its earnings as a dividend. SIGA Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

SIGA Technologies quarterly revenues are $10M, which are larger than Tonix Pharmaceuticals Holding quarterly revenues of $2.8M. SIGA Technologies's net income of $1.3M is higher than Tonix Pharmaceuticals Holding's net income of -$14.2M. Notably, SIGA Technologies's price-to-earnings ratio is 5.00x while Tonix Pharmaceuticals Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SIGA Technologies is 2.48x versus 0.60x for Tonix Pharmaceuticals Holding. Usually stocks with elevated PS ratios are considered overvalued.